Once again, anti-TNF-α therapy (adalimumab) decreased 99mTc-labeled leukocyte accumulation into the joints of RA patients 2 weeks after the treatment onset, which subsequent studies suggested that this was due to increased 99mTc monocyte/macrophage egress from the joint as numbers of monocytes entering remained unaffected by adalimumab treatment (Thurlings et al., 2009; Herenius et al., 2011). The gene discussed is TNF; the disease is rheumatoid arthritis.